HCPCS Level II J0135: Adalimumab 20 mg Injection - OpenPayer

Summary & Overview

HCPCS Level II J0135: Adalimumab 20 mg Injection

HCPCS Level II code J0135 denotes a 20 mg injection of adalimumab, a TNF-blocking biologic used across multiple inflammatory and autoimmune conditions. Nationally, this code matters because biologic therapies constitute a substantial and growing share of outpatient drug spend and require accurate coding for coverage, billing, and clinical tracking.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer policies, billing benchmarks, and clinical context for use of J0135, with attention to site-of-service implications and documentation needs.

Readers will learn how J0135 is defined and applied in outpatient settings, how major payers approach coverage and reimbursement at a high level, and what benchmarks and policy updates affect billing for adalimumab 20 mg injections. The report also provides clinical context on typical administration settings and summarizes where readers can expect variation in payer handling. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0135HCPCS Level IIadalimumabbiologic injectionoutpatient infusiondrug billingmedication administrationpharmacy benefit

Billing Code Overview

HCPCS Level II code J0135 represents an injection of adalimumab, 20 mg. This code is used to report administration of a 20 mg dose of adalimumab, a monoclonal antibody targeting tumor necrosis factor (TNF). The service type is medication injection/biologic drug administration. The typical site of service is outpatient infusion or injection settings such as physician offices, specialty clinics, and outpatient infusion centers.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with an immune‑mediated inflammatory disease such as moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, or hidradenitis suppurativa who presents to an outpatient infusion/injection clinic, specialty pharmacy clinic, or physician office for administration of a prefilled syringe of adalimumab. The clinical workflow begins with verification of the prescription and prior authorization, medication reconciliation and allergy check, assessment of baseline vital signs and infection risk screening (including tuberculosis and recent infections), patient education on expected effects and adverse reactions, and documentation of lot number and expiration. The medication J0135 (injection, adalimumab, 20 mg) is obtained from pharmacy, labeled, and administered subcutaneously by a registered nurse or licensed medical personnel. Observation for acute hypersensitivity or injection‑site reaction occurs for a short period (typically 15–30 minutes) after injection. Documentation includes indication, medication name and dose, route, site, lot number, NDC when required, and any immediate adverse events. Billing includes the HCPCS Level II code J0135 and may include relevant modifiers for unusual circumstances or payer requirements.

Coding Specifications

Modifier	Description	When to Use
`22`

HCPCS J0289: Amphotericin B Liposome Injection, 10 mg

HCPCS-J7296-LEVONORGESTREL-IUD-KYLEENA-19-5-MG

HCPCS Level II J7296: Levonorgestrel IUD (Kyleena) 19.5 mg

HCPCS-J2788-RHOD-IMMUNE-GLOBULIN-MINIDOSE-50-MCG-250-IU

HCPCS Level II J2788: Rho(D) Immune Globulin Minidose Injection

HCPCS-J1439-FERRIC-CARBOXYMALTOSE-INJECTION-1MG

HCPCS J1439: Ferric Carboxymaltose Injection, 1 mg

HCPCS-J0665-BUPIVACAINE-INJECTION-LOCAL-ANESTHESIA-05MG

HCPCS J0665: Injection of Bupivacaine, 0.5 mg

HCPCS-J1265-DOPAMINE-40MG-INJECTION

HCPCS J1265: Injection, Dopamine HCl 40 mg

HCPCS-J3410-HYDROXYZINE-INJECTION-UP-TO-25-MG

HCPCS J3410: Injection of Hydroxyzine HCl, up to 25 mg

HCPCS-J1445-FERRIC-PYROPHOSPHATE-CITRATE-TRIFERIC-AVNU-INJECTION

HCPCS J1445: Injection, Ferric Pyrophosphate Citrate (Triferic Avnu), 0.1 mg of Iron

HCPCS-J0879-DIFELIKEFALIN-INJECTION-ESRD-DIALYSIS

HCPCS J0879: Injection of difelikefalin for ESRD on Dialysis

HCPCS-J7197-ANTITHROMBIN-III-HUMAN-PER-IU

HCPCS J7197: Antithrombin III (human), per international unit

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207RC0000X`	Rheumatology	Rheumatologists commonly prescribe and oversee adalimumab therapy for inflammatory arthritis.
`208000000X`	Internal Medicine	Hospitalists and internists may administer or manage biologic therapy in outpatient clinics.
`207L00000X`	Allergy & Immunology	Allergists manage biologic therapy for certain immune‑mediated conditions and evaluate hypersensitivity risks.
`363LF0000X`	Nurse Practitioner	Nurse practitioners frequently administer injections and provide patient education in specialty clinics.
`367A00000X`	Physician Assistant	Physician assistants perform injections and follow‑up care under supervising physician protocols.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M06.9`	Rheumatoid arthritis, unspecified	Rheumatoid arthritis is a common indication for adalimumab therapy to control synovitis and prevent joint damage.
`L40.0`	Psoriasis vulgaris	Moderate to severe plaque psoriasis is treated with adalimumab to reduce skin lesions and inflammation.
`L40.5`	Arthropathic psoriasis	Psoriatic arthritis indications overlap with psoriasis and require TNF inhibitor therapy such as adalimumab.
`M07.0`	Distal interphalangeal psoriatic arthropathy	Specific psoriatic arthritis presentations commonly treated with biologics including adalimumab.
`K50.00`	Crohn disease of small intestine without complications	Crohn disease is an approved indication for adalimumab to induce and maintain remission.
`K51.90`	Ulcerative colitis, unspecified, without complications	Ulcerative colitis may be treated with adalimumab for moderate to severe disease.
`L73.2`	Hidradenitis suppurativa	Moderate to severe hidradenitis suppurativa is an indication for adalimumab therapy.
`M45.9`	Ankylosing spondylitis, unspecified	Axial spondyloarthritis and ankylosing spondylitis are indications where adalimumab is used to reduce inflammation and improve function.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly used to report the administration service for a subcutaneous injection like adalimumab when payer requires a separate administration code in addition to the drug HCPCS `J0135`.
`99001`	Handling and/or processing of a drug or biological for patient administration, per dose (example placeholder — verify payer list)	Some facilities use specific facility or local codes for drug handling; verify payer policy. (Note: use only if recognized by the payer.)
`96360`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	Not typical for subcutaneous adalimumab but included when an infusion encounter with separate infusion services occurs concurrently.
`36415`	Collection of venous blood by venipuncture	Often performed prior to biologic initiation for baseline labs (CBC, CMP, TB testing) supporting therapy with adalimumab.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate	Counseling codes commonly used during chronic disease management visits where lifestyle counseling is provided alongside biologic therapy.

OpenPayer